Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy

Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers and is on the rise annually. It is characterized by low differentiation, high malignancy, and rapid growth. Consequently, treatment options are limited, and the patient’s prognosis is poor. The emergence of immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wanshan, Wu, Lexia, Wu, Jiaming, Lin, Sihong, Fang, Cantu, Zhang, Huatang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480285/
https://www.ncbi.nlm.nih.gov/pubmed/37680956
http://dx.doi.org/10.2147/CMAR.S418116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480285/
https://www.ncbi.nlm.nih.gov/pubmed/37680956
http://dx.doi.org/10.2147/CMAR.S418116

Ejemplares similares